Effect of an oral supplementation with a proprietary melon juice concentrate (Extramel®) on stress and fatigue in healthy people: a pilot, double-blind, placebo-controlled clinical trial by Milesi, Marie-Anne et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Nutrition Journal
Open Access Research
Effect of an oral supplementation with a proprietary melon juice 
concentrate (Extramel®) on stress and fatigue in healthy people: a 
pilot, double-blind, placebo-controlled clinical trial
Marie-Anne Milesi*1, Dominique Lacan2, Hervé Brosse3, Didier Desor4 and 
Claire Notin1
Address: 1Nutrition Department, Seppic (Air Liquide Group), Paris, France, 2Bionov, Montpellier, France, 3Isoclin, Chasseneuil du Poitou, France 
and 4Behavioural and Cognitive Neurosciences, Université Henri Poincaré, Vandoeuvre-lès-Nancy, France
Email: Marie-Anne Milesi* - marie-anne.milesi@airliquide.com; Dominique Lacan - dominique.lacan@bionov.fr; 
Hervé Brosse - herve.brosse@isoclin.fr; Didier Desor - didier.desor@scbiol.uhp-nancy.fr; Claire Notin - claire.notin@airliquide.com
* Corresponding author    
Abstract
Background: Recent studies have demonstrated a correlation between perceived stress and
oxidative stress. As SOD is the main enzyme of the enzymatic antioxidant defence system of the
body, we evaluated the effect of an oral daily intake of a proprietary melon juice concentrate rich
in SOD (EXTRAMEL®) on the signs and symptoms of stress and fatigue in healthy volunteers.
Methods: This randomized, double blind, placebo controlled clinical study was conducted with
seventy healthy volunteers aged between 30 and 55 years, who feel daily stress and fatigue. They
took the dietary supplement based on the melon juice concentrate (10 mg Extramel®
corresponding to 140 IU SOD per capsule) or a placebo one time daily during 4 weeks. Stress and
fatigue were measured using four observational psychometric scales: FARD, PSS-14, SF-12 and
Epworth scale. The study was conducted by Isoclin, a clinical research organization, located in
Poitiers, France.
Results: No adverse effect was noted. The supplementation with the proprietary melon juice
concentrate bringing 140 IU SOD/day significantly improved signs and symptoms of stress and
fatigue linked to performance, physical (pain, sleep troubles), cognitive (concentration, weariness,
sleep troubles) or behavioural (attitude, irritability, difficulty of contact) compared to the placebo.
In the same way, quality of life and perceived stress were significantly improved with SOD
supplementation.
Conclusion: This pilot study showed that an oral supplementation with a proprietary melon juice
concentrate rich in SOD may have a positive effect on several signs and symptoms of perceived
stress and fatigue.
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Background
In developed countries, people from all social classes are
concerned about fatigue, stress and anxiety. It is estimated
that 30% of the population will suffer from these symp-
toms at one point in their life [1]. It is known also that
professional activity generates stress and fatigue, which
are closely linked [1].
Several studies show that there is an emerging link
between individual stress and intracellular oxidative
stress. In a clinical trial on 42 women in the work force, a
correlation between perceived stress and intracellular oxi-
dative stress was demonstrated. In this trial, inflammatory
markers like TNF-α or HbA1C were enhanced in women
with a high burnout, indicating a role of inflammatory
responses and oxidative stress in the pathophysiology of
burnout [2]. In the same way, a clinical study on workers
in a prehospital emergency service, showed a positive cor-
relation between malondialdehyde (MDA), a biomarker
of lipid peroxidation, and burnout levels [3]. Finally, a
recent study on mice showed a positive correlation
between the glutathione reductase activity and anxiety,
suggesting that cellular oxidative stress seen in mice might
be clinically translated as anxious and stressed behaviour
in patients [4].
SOD is one of the main antioxidant enzymes found in liv-
ing cells and organisms. Known since 1969 [5], SOD from
erythrocytes was largely studied and used as a treatment
for certain diseases like arthritis in a rat model [6] or in
chronic radiotherapy damage in humans [7]. Since 2000,
a proprietary melon juice concentrate containing high
level of SOD has been developed, its use as a dietary sup-
plement has been a new subject of interest and its antioxi-
dant and anti-inflammatory properties have been
demonstrated [8]. In healthy volunteers, the melon juice
concentrate combined with wheat gliadin polymers,
showed a protective effect against DNA damage resulting
from oxidative stress induced by hyperbaric oxygen [9].
The same authors also showed that the melon juice con-
centrate rich in SOD combined with gliadin polymer
reduced cell injury resulting from aortic cross-clamping in
pigs [10]. Recently, it was demonstrated that Extramel®
(the melon juice concentrate combined with vegetable
fat) prevents aortic lipids and liver steatosis in a diet-
induced hamster model of atherosclerosis [11]. It seemed
then very interesting to study the effect on perceived stress
of EXTRAMEL® (Bionov, Avignon, France), this melon
juice concentrate containing high concentration of SOD
which acts on oxidative stress at the cellular level.
The present pilot study aims to determine if a daily intake
of this proprietary melon juice concentrate dosed to bring
140 IU of SOD is able to decrease the signs and symptoms
of perceived stress and fatigue in healthy volunteers.
Materials and methods
Test Material
EXTRAMEL® is a proprietary freeze-dried melon juice con-
centrate obtained by physical treatment (crushing of the
melon, recovery of the pulp, centrifugation, filtration,
freeze-drying) of a specific variety of melon (not a geneti-
cally modified organism) which contains high levels of
SOD and other antioxidants (US Patent No 5 616 323). As
SOD is very sensitive to oxygen, high temperature and
acidity, the melon juice concentrate has to be coated. The
product used in the study (EXTRAMEL® microgranules)
was coated with palm oil. The dietary supplements given
to the volunteers were small hard capsules containing 10
mg Extramel® (140 IU of SOD [12]) and starch for the
verum (EXT) and starch only for the placebo (P).
The volunteers assigned by randomisation in two groups
of 35 were given a food supplement (EXT) or a placebo
(P) for 28 days: one capsule per day taken in the morning.
The capsules were indistinguishable and were adminis-
tered in a double blind approach.
Methods: Psychometric tools
In order to evaluate the signs and symptoms of perceived
stress and fatigue, the neurobehavioral sphere of the vol-
unteers was explored. Moreover, their own perception of
stress and its impact on their quality of life and sleep were
evaluated. Four validated and well-known evaluation
scales were then chosen:
1.  Ferreri Anxiety Rating Diagram (FARD) [13,14]
explores four poles divided in three items:
- Somatic pole (attitude, neurovegetative troubles,
pain),
- Relational pole (apprehension, internal tension, dif-
ficulty of contact),
- Vigilance pole (irritability, sensorial troubles, sleep
troubles),
- Cognitive pole (concentration, weariness, doubt-
indecision),
with a total of 12 questions and a score from 0 to 72;
2. Cohen Perceived Stress scale (PSS-14) [15] evaluates the
perceived stress during the last two weeks with 14 ques-
tions and a score from 14 to 70;
3.  SF-12®  Health Survey [16] allows to measure eight
aspects of the quality of life: general physical and mental
health state (fatigue), physical and social functioning,
physical and emotional health, pain and vitality. The SF-Nutrition Journal 2009, 8:40 http://www.nutritionj.com/content/8/1/40
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12 questionnaire is composed of 12 questions with a
score from 3 to 38;
4.  Epworth Sleepiness Scale [17] is a questionnaire
intended to measure daytime sleepiness composed by
eight questions with a score from 0 to 24.
The Beck Depression Inventory (BDI) [18], a 13 question
multiple choice self-report inventory, which is one of the
most widely used instruments for measuring the severity
of depression, was used to avoid the inclusion of depres-
sive volunteers.
Study Design
The clinical trial was an intervention pilot study based on
individual evaluation scales. The protocol followed was
randomized, double blind and placebo controlled. It was
approved by the Comité de Protection des Personnes
Ouest III, the ethical committee of Poitiers, France under
the number 2006-A00677-44 to be conducted by Dr Thi-
erry Cantin.
A call for volunteers was made in the region of the inves-
tigation centre (Poitiers area, Poitou, 86, France) and the
volunteers for the study were pre-screened by the investi-
gator.
The inclusion criteria were to be between 30 to 55 years
old, to have a BMI (Body Mass Index) ≤ 30, to have a sta-
ble professional activity for more than one year, to per-
ceive a certain level of stress & fatigue, to be in full health,
not taking any drugs or dietary supplements, not taking
anti-stress or anti-fatigue drinks.
The exclusion criteria were to be pregnant or breast-feed-
ing, to have a previous case of psychiatric disease, to have
pathologies ongoing or active during the last month, to
have received medical treatment (allopathic or homeo-
pathic) during the previous month, to have taken a dietary
supplement during the last month, to be in a stressful sit-
uation during the next month (wedding, birth, scheduled
hospitalisation, important exam...).
Acceptable volunteers were called in for a screening and
baseline evaluation using the five evaluation scales previ-
ously described: FARD, Epworth, PSS-14, SF-12 and BDI
scale. Then, 70 volunteers were definitively included and
participated in the clinical trial. These volunteers provided
a written informed consent.
The volunteers were tested three times during a visit to the
doctor. The first time was before the supplementation
(D0), corresponding to the screening evaluation. A test
was planned 7 days (D7) after taking the supplement and
another one at the end of the trial (D28). The evaluation
scales were filled out by the volunteers themselves. During
every consultation, the doctor made a general clinical
exam (arterial tone and cardiac frequency measure) and
filled up an event journal with remarks on the volunteers,
eventual undercurrent effects, the eventual pathologies
and their associated treatment.
Method of Screening the Volunteers
Axis were determined by combining the different scales:
￿ Physical Axis composed by FARD somatic pole (0 -
18), FARD vigilance pole (0 - 18) and SF-12 scale (3 -
38) with a total score from 3 to 74;
￿ Cognitive Axis composed by FARD cognitive pole (0
- 18) with a total score from 0 to 18;
￿ Relational Axis composed by FARD relational pole
(0 - 18) with a total score from 0 to 18;
￿ Perceived Stress Axis composed by Epworth sleepi-
ness scale (0 - 24) and Cohen's PSS-14 perceived stress
scale (14 - 70) with a total score form 14 to 94. To be
included, the volunteers had to get scores within the
following parameters: BDI < 5; Physical Axis > 15/74;
Cognitive Axis > 5/18; Relational Axis > 5/18; Per-
ceived Stress Axis > 33/94.
The means of each score for the volunteers were: Physical
Axis = 24.95; Cognitive Axis = 6.27; Relational Axis = 5.89;
Perceived Stress Axis = 40.7.
Statistical Analysis
The data were expressed as means ± SD of the evolution of
the scores on each scale between D0 and D7 and between
D0 and D28 in absolute and relative values. The paired
Student's t-Test was used to analyse each group relative to
the amplitude of variation between D0 and D7 and D0
and D28 and to compare results between groups at D0,
D7 and D28.
Results
Study Population
Seventy volunteers aged between 30 and 55 years (mean
40.26) with a BMI from 17 to 42 (7 volunteers were
included although their BMI was over 30) were enrolled
and randomized into two test groups and no subject was
dropout. There was no statistical difference between the
two groups at baseline in scores for age, ethnicity, ...
During the 4 weeks of the study, the doctor filled up a file
of events and no adverse effect was noted. Scores used for
the statistical analysis are reported in Tables 1, 2, 3, 4, 5
and 6. The two groups are not equivalent in their base
level score but this difference is not statically differentNutrition Journal 2009, 8:40 http://www.nutritionj.com/content/8/1/40
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except for vigilance pole, irritability and apprehension
(data not shown) items of the FARD scale for which the
scores are worst for the EXT group.
FARD Scale
The statistical analysis on somatic, vigilance and cognitive
poles showed that scores of these poles were significantly
improved at D28 in both groups (Table 1). This clearly
indicates that an important placebo effect is present in the
study.
Nevertheless, when the scores of the groups are compared
at D28, a significant difference between them appears
(Table 2): the three poles are much more improved in the
EXT group than in the P group with respectively 18%
more for the somatic pole, 25% more for the vigilance
pole, and 20% more for the cognitive pole.
Concerning the relational pole, its improvement is not
significant in either group (data not shown).
The further analysis of each pole also gave interesting
results. In the P group, all items were significantly
improved from D7 (Table 3) excluding sleep troubles and
doubt-indecision (data not shown). In the EXT group, all
items were also significantly improved from D7, exclud-
ing only doubt-indecision, but contrary to the P group,
the improvement of certain items continued to increase in
D28.
At D28, the results showed that pain, irritability, sleep
troubles and weariness scores were significantly improved
in the EXT group as compared to the P group, being
respectively, 30, 22, 38 and 26% higher (Table 4). Atti-
tude, difficulty of contact and concentration items also are
more improved in the EXT group than in the P group,
being respectively, 26, 26 and 22% higher, but there is no
significance, it is only a trend. All other items (neurovege-
tative troubles, sensorial troubles, apprehension, internal
tension and doubt-indecision) scores were not signifi-
cantly different at D28 between the EXT and P groups, and
seemed then to be only improved by a placebo effect (data
not shown).
Perceived Stress Scale
The analysis of the results of the PSS-14 scale (Table 5 and
Figure 1) showed that a significant decrease in perceived
stress occurred between D0 and D7 in both groups. How-
ever, after D7, in the P group, the placebo effect seemed to
have reached its maximum level and perceived stress
stopped to decrease, whereas in the EXT group, perceived
stress continued to decrease with a statistically significant
improvement of 12% (p = 0.01) compared to the P group
at D28 and a global decrease of 30% (Table 6 and Figure
1).
Quality of Life Scale
The analysis of the results of the SF-12 scale (Table 5 and
Figure 2) showed that a high and significant improvement
Table 1: FARD poles: scores at D0, D7 and D28 and evolution between D0 and D28 for P and EXT groups
Poles scores Evolution between D0 and D28
D0 D7 D28 P group EXT 
group
P group EXT 
group
P group EXT 
group
P group EXT 
group
t student p value t student p value
Somatic 
pole
4.78 ± 3.62 3.72 ± 2.64 2.40 ± 2.93 1.67 ± 2.32 1.75 ± 2.27 0.67 ± 1.24 3.280 0.003 ** 5.672 0.000 ***
Vigilance 
pole
5.34 ± 3.12 3.69 ± 2.56 2.96 ± 2.61 1.85 ± 1.88 2.79 ± 2.92 1.00 ± 1.24 2.541 0.018 * 3.813 0.001 ***
Cognitive 
pole
6.38 ± 3.03 6.16 ± 2.42 2.16 ± 2.53 1.65 ± 2.26 2.13 ± 2.42 0.83 ± 1.29 5.992 0.000 *** 12.710 0.000 ***
Table 2: FARD poles: transverse comparisons between P and EXT groups at D0, D7 and D28
D0 D7 D28
t student p value t student p value t student p value
Somatic pole 1.342 0.185 NS 1.004 0.320 NS 1.979 0.050 *
Vigilance pole 2.323 0.023 * 1.770 0.083 NS 2.701 0.011 *
Cognitive pole 0.319 0.751 NS 0.754 0.454 NS 2.225 0.032 *Nutrition Journal 2009, 8:40 http://www.nutritionj.com/content/8/1/40
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in the quality of life occurred between D0 and D7 in both
groups. However, after D7, in P group the placebo effect
seemed to have reached its maximum level and the score
stopped to decrease whereas in the EXT group, the quality
of life continued to improve with a statistically significant
difference of 9% (p = 0.049) compared to the P group at
D28 and a global improvement of 42% (Table 6 and Fig-
ure 2).
Sleepiness Scale
The analysis of the results of the Epworth scale (Table 5
and Table 6) showed non significant difference between
the P and EXT groups.
Discussion
The FARD scale showed that the symptoms linked to per-
formance, physical (pain, sleep troubles), cognitive (con-
centration, weariness, sleep troubles) or behavioural
(attitude, irritability, difficulty of contact), were visibly
improved by the supplementation with the proprietary
melon juice concentrate rich in SOD compared to pla-
cebo, whereas psychological behaviour (neurovegetative
and sensorial troubles, internal tension and doubt-indeci-
sion) was not improved over the placebo effect. Perceived
stress and quality of life (quality of life being an evalua-
tion of both physical and cognitive fatigue) were also
improved by this supplementation with the melon juice
concentrate rich in SOD compared to the placebo,
whereas no effect was shown on sleepiness.
Fatigue and stress were not very high in the population of
the study and corresponded to a normal everyday level of
fatigue and stress of working people in developed coun-
tries.
Because of this low base level of stress and fatigue, the pla-
cebo effect seemed to be very high whereas with a higher
base level the difference between supplemented and pla-
Table 3: FARD items: scores at D0, D7 and D28 and evolution between D0 and D28 for P and EXT groups
Items scores Evolution between D0 and D28
D0 D7 D28 P group EXT 
group
P group EXT 
group
P group EXT 
group
P group EXT 
group
t student p value t student p value
Attitude 1.69 ± 1.55 1.53 ± 1.19 0.96 ± 1.54 0.63 ± 0.79 0.63 ± 1.06 0.17 ± 0.51 2.542 0.010 ** 4.675 0.000 ***
Pain 1.81 ± 1.51 1.25 ± 1.39 1.00 ± 1.29 0.52 ± 1.01 0.79 ± 1.14 0.17 ± 0.51 2.235 0.035 * 4.189 0.001 ***
Irritability 2.38 ± 1.26 1.56 ± 0.95 1.40 ± 1.19 0.89 ± 1.01 1.13 ± 1.19 0.39 ± 0.78 3.340 0.003 ** 4.123 0.001 ***
Sleep 
troubles
1.94 ± 1.79 1.28 ± 1.46 1.28 ± 1.67 0.74 ± 1.23 1.33 ± 1.88 0.39 ± 0.50 1.234 0.230 NS 1.686 0.110 NS
Difficulty of 
contact
1.50 ± 1.05 1.53 ± 0.67 0.76 ± 0.83 0.26 ± 0.66 0.67 ± 0.76 0.28 ± 0.57 3.019 0.006 ** 5.236 0.000 ***
Concentrati
on
2.25 ± 0.98 2.19 ± 1.09 0.92 ± 1.26 0.56 ± 0.97 0.79 ± 1.28 0.28 ± 0.57 5.027 0.000 *** 6.761 0.000 ***
Weariness 2.13 ± 1.48 2.00 ± 1.50 0.68 ± 0.95 0.37 ± 0.74 0.75 ± 0.99 0.17 ± 0.38 4.164 0.000 *** 8.018 0.000 ***
Table 4: FARD items: transverse comparisons between P and EXT groups at D0, D7 and D28
D0 D7 D28
t student p value t student p value t student p value
Attitude 0.451 0.653 NS 0.983 0.330 NS 1.854 0.072 t
Pain 1.549 0.127 NS 1.501 0.140 NS 2.380 0.023 *
Irritability 2.909 0.005 ** 1.672 0.101 NS 2.280 0.028 *
Sleep troubles 1.603 0.114 NS 1.333 0.189 NS 2.351 0.026 *
Difficulty of contact 0.142 0.887 NS 2.422 0.019 * 1.887 0.066 t
Concentration 0.241 0.811 NS 1.174 0.246 NS 1.741 0.091 t
Weariness 0.336 0.738 NS 1.320 0.193 NS 2.637 0.010 **Nutrition Journal 2009, 8:40 http://www.nutritionj.com/content/8/1/40
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Table 5: PSS-14, SF-12 and Epworth scales: scores at D0, D7 and D28 and evolution between D0 and D28 for P and EXT groups
Scores Evolution between D0 and D28
D0 D7 D28 P group EXT group
P group EXT group P group EXT group P group EXT group t student p value t student p value
PSS-14 36.88 ± 
7.95
34.00 ± 
6.03
30.88 ± 
9.47
27.04 ± 
8.06
30.17 ± 
8.90
23.61 ± 
6.58
3.975 0.001 *** 5.767 0.000 ***
SF-12 17.09 ± 
5.46
15.38 ± 
4.53
12.52 ± 
4.90
11.52 ± 
4.27
11.52 ± 
4.96
8.89 ± 3.29 4.570 0.000 *** 4.001 0.001 ***
Epworth 8.03 ± 3.55 7.66 ± 3.43 6.28 ± 4.25 6.48 ± 3.77 5.67 ± 4.55 6.17 ± 4.64 3.582 0.002 ** 1.971 0.065 t
Table 6: PSS-14, SF-12 and Epworth scales: transverse comparisons between P and EXT groups at D0, D7 and D28
D0 D7 D28
t student p value t student p value t student p value
PSS-14 1.630 0.108 NS 1.580 0.120 NS 2.714 0.010 **
SF-12 1.371 0.175 NS 0.787 0.435 NS 2.037 0.049 *
Epworth 0.430 0.669 NS 0.181 0.857 NS 0.350 0.729 NS
Scores of PSS-14 scale (Mean ± SD) before, during and after  supplementation Figure 1
Scores of PSS-14 scale (Mean ± SD) before, during 
and after supplementation. EXT group: supplemented 
with melon juice concentrate rich in SOD. Transverse com-
parison between groups significantly different: ** p < 0.01
Scores of SF-12 scale (Mean ± SD) before, during and after  supplementation Figure 2
Scores of SF-12 scale (Mean ± SD) before, during and 
after supplementation. EXT group: supplemented with 
melon juice concentrate rich in SOD Transverse comparison 
between groups significantly different: * p < 0.05Nutrition Journal 2009, 8:40 http://www.nutritionj.com/content/8/1/40
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cebo groups might be more significant. Nevertheless the
study highlighted that the placebo effect was only present
during the first 7 days of supplementation and not
beyond.
It was interesting to note that, despite the high placebo
effect and the low base level of stress and fatigue of the
volunteers, the study highlighted that supplementation
with the melon juice concentrate rich in SOD had a signif-
icantly higher effect compared to placebo on most of the
variables of the study and tended to have a significantly
higher effect on some others. This may indicate that this
specific supplementation has an effect on signs and symp-
toms of perceived stress and fatigue covering physical and
mental health such as pain, irritability, sleep troubles,
weariness, perceived stress and quality of life; moreover it
has a probable effect on others such as attitude, concentra-
tion and difficulty of contact; and it has no effect on signs
and symptoms linked to relational behaviour and sleepi-
ness.
Finally, it was interesting to discover that the supplemen-
tation with the melon juice concentrate rich in SOD has a
significant effect on sleep troubles but not on sleepiness,
which could be a side effect of many sedatives. This result
added to the positive results on perceived stress, quality of
life which evaluates physical and cognitive fatigue and
overall physical and cognitive performances could suggest
that Extramel® supplementation acts as a cognitive and
physical tonic.
Conclusion
In conclusion, this pilot clinical trial highlights that an
oral supplementation with EXTRAMEL®, bringing 140 IU
of SOD, which is known to have an antioxidant activity
on cellular level and fighting against oxidative stress,
could have a positive effect on several signs and symp-
toms of perceived stress and fatigue, and particularly per-
ceived stress, quality of life (physical and mental health
condition) and some aspects of neurobehaviour. Further
studies with a larger number of volunteers and a longer
duration would be interesting to confirm these effects and
better understand the action of an oral intake of this pro-
prietary melon juice concentrate rich in SOD on stress and
fatigue.
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